ArticleMedicine2026
Predictive value of non-high-density lipoprotein cholesterol and remnant cholesterol for progression of non-culprit coronary lesions with QFR ≤ 0.80: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the predictive value of non-high-density lipoprotein cholesterol (non-HDL-C) and remnant cholesterol (remnant-C) for the progression of non-culprit coronary lesions with quantitative flow ratio ≤ 0.80. A total of 214 patients with coronary artery disease undergoing percutaneous coronary intervention from January 2022 to March 2024 were consecutively enrolled, with 321 non-culprit lesions. All patients completed at least 24 months of clinical follow-up. Based on follow-up quantitative coronary angiography assessment, patients were divided into lesion progression and non-progression groups. Baseline clinical data, laboratory parameters, and coronary angiography characteristics were collected. Univariate and multivariate logistic regression analyses were performed to assess the independent predictive value of non-HDL-C and remnant-C for lesion progression. Predictive performance was compared using receiver operating characteristic curves, and subgroup analyses were conducted. During follow-up, 62 patients (29.0%) experienced non-culprit lesion progression. The median angiographic follow-up interval was 14.2 months (interquartile range, 10.8-18.1; range, 6.1-23.8) overall and did not differ significantly between the progression and non-progression groups (14.6 vs 14.0 months, P = .47). Multivariable logistic regression showed that, after adjustment for prespecified clinical covariates, both non-HDL-C (odds ratio = 1.68, 95% confidence interval: 1.22-2.31, P = .001) and remnant-C (odds ratio = 1.52, 95% confidence interval: 1.24-1.86, P < .001) were independently associated with lesion progression. The apparent areas under the curves were 0.72 for non-HDL-C and 0.70 for remnant-C; after adding clinical variables, the apparent areas under the curves were 0.84 and 0.83, respectively. Numerically larger effect estimates were observed in patients with diabetes mellitus, multivessel disease, and renal dysfunction, but all interaction P values were >.05. Non-HDL-C and remnant-C are independent predictors of progression of non-culprit coronary lesions with quantitative flow ratio ≤ 0.80. Combining them with traditional risk factors significantly improves predictive performance, offering clinical value for high-risk patient identification and secondary prevention optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.